ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases

Contributed by: Business Wire

Logo

Tags

Biotechnology

Publishing

Medical Supplies

General Health

Health

Infectious Diseases

Communications

Other Health

ILiAD Biotechnologies, Inc.

More Like This

UK MHRA Grants Innovation Passport Designation to ILiAD Biotechnologies BPZE1 Next Generation Intranasal Pertussis Vaccine

ILiAD Biotechnologies Announces Lancet Microbe Publication of BPZE1 Phase 2b Clinical Results in Human Challenge Model

ILiAD Biotechnologies Announces $115M Oversubscribed Series B Financing to Advance BPZE1 Pertussis Vaccine

ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

PR Newswire associated0

Airway Therapeutics Receives European Medicines Agency Pediatric Committee Approval for Zelpultide Alfa's Study Plan in Bronchopulmonary Dysplasia for Very Preterm Infants

PR Newswire associated0

Airway Therapeutics Awarded $1.9 Million NIH Grant to Advance Phase 2b/3 Study of Zelpultide Alfa for Prevention of Bronchopulmonary Dysplasia

Airway Therapeutics to Launch a Multinational Phase 3 Trial of Zelpultide Alfa for Preterm Neonates at Risk of Bronchopulmonary Dysplasia